Literature DB >> 6137660

"Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin.

R Eldridge, M Iivanainen, R Stern, T Koerber, B J Wilder.   

Abstract

A survey of 15 families in the USA with Baltic myoclonus epilepsy showed that the 27 individuals who were affected had the following clinical picture from about the age of 10: photosensitive, occasionally violent, myoclonus, usually worse upon waking; generalised tonic-clonic seizures, sometimes associated with absence attacks; and light-sensitive, generally synchronous, spike-and-wave discharges on EEG that preceded clinical manifestations. Necropsy revealed marked loss of Purkinje cells of the cerebellum, but no inclusion bodies. Since the disease was confined to sibs and consanguinity was present in two families, autosomal recessive inheritance is probable. The disease progressed more rapidly in these families than it did in the early cases, seen in the Baltic region. This difference could be due to a toxic effect of phenytoin because phenytoin given alone or with other antiepileptic drugs was associated with progressive motor and intellectual deterioration, marked ataxia, and even death. Treatment with valproic acid, and the concomitant reduction or elimination of phenytoin, has been associated with marked improvement in at least 8 patients. Baltic myoclonus epilepsy must be distinguished from Lafora body disease, which is invariably fatal and discernible on clinical grounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137660     DOI: 10.1016/s0140-6736(83)90749-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  29 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Ramsay Hunt syndrome: to bury or to praise.

Authors:  S F Berkovic; F Andermann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

Review 3.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

Review 4.  Effect of phenytoin on the mental and physical function of patients with Baltic myoclonus epilepsy.

Authors:  M Iivanainen; R Eldridge
Journal:  Ital J Neurol Sci       Date:  1987-08

5.  Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis.

Authors:  P Koskenkorva; E Niskanen; J Hyppönen; M Könönen; E Mervaala; H Soininen; R Kälviäinen; R Vanninen
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 6.  The history of progressive myoclonus epilepsies.

Authors:  Pierre Genton; Pasquale Striano; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

7.  Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22.

Authors:  A E Lehesjoki; M Koskiniemi; P Sistonen; J Miao; J Hästbacka; R Norio; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  Stefin B interacts with histones and cathepsin L in the nucleus.

Authors:  Slavko Ceru; Spela Konjar; Katarina Maher; Urska Repnik; Igor Krizaj; Mojca Bencina; Miha Renko; Alain Nepveu; Eva Zerovnik; Boris Turk; Natasa Kopitar-Jerala
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 9.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

Review 10.  Genetic counseling in the epilepsies. I. Genetic risks.

Authors:  M Blandfort; T Tsuboi; F Vogel
Journal:  Hum Genet       Date:  1987-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.